Compass Therapeutics, Inc. (CMPX) - Dilution Analysis

10-Q filing | 186.4M shares outstanding

S-3 filing: This S-3 filing from 2025-12-30 relates to an at-the-market offering of common stock.

10-Q filing | 138.3M shares outstanding

10-Q filing | 138.2M shares outstanding

10-K filing | 137.4M shares outstanding

10-Q filing | 137.6M shares outstanding

S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, warrants and/or units up to $300,000,000. They are also offering shares of common stock having an aggregate offering price of up to $55,000,000 through an at the market offering.

10-Q filing | 137.6M shares outstanding

10-Q filing | 136.6M shares outstanding

10-K filing | 127.0M shares outstanding

10-Q filing | 127.4M shares outstanding

10-Q filing | 126.7M shares outstanding

10-Q filing | 126.4M shares outstanding

10-K filing | 126.3M shares outstanding

S-3 filing: This prospectus relates to the offering and resale by the selling stockholders of up to 25,000,000 shares of common stock of Compass Therapeutics, Inc.

10-Q filing | 101.0M shares outstanding

10-Q filing | 100.9M shares outstanding

10-Q filing | 101.3M shares outstanding

10-K filing | 101.3M shares outstanding

10-Q filing | 98.0M shares outstanding

8-K filing: Compass Therapeutics, Inc. entered into an underwriting agreement for a public offering of 35,715,000 shares of common stock at $3.50 per share, with an option for the underwriters to purchase an additional 5,357,250 shares.

10-Q filing | 61.7M shares outstanding

S-3 filing: The company is offering shares of its common stock from time to time through B. Riley Securities acting as their agent or principal, having an aggregate offering price of up to $75,000,000.

8-K filing: Compass Therapeutics consummated the merger with TRIGR Therapeutics on June 25, 2021, issuing 10,265,133 unregistered shares of Compass's common stock to TRIGR shareholders, with potential earnout payments up to $9 million tied to certain events.

8-K filing: Compass Therapeutics, Inc. entered into a definitive merger agreement with TRIGR Therapeutics, Inc. to acquire all outstanding shares of TRIGR through a two-step merger structure. Consideration includes 10,265,154 shares of Compass' common stock and up to $9 million in earnout payments.

10-Q filing | 51.3M shares outstanding

10-K filing | 52.1M shares outstanding

POS AM filing: This prospectus relates to the offering and resale by the selling stockholders identified herein of up to 52,112,143 shares of common stock, par value $0.0001 per share, of Compass Therapeutics, Inc.

10-Q filing | 52.1M shares outstanding

S-1/A filing: Compass Therapeutics, Inc. is offering 9,000,000 shares of common stock in a public offering, with an expected price between $5.00 and $6.00 per share. The underwriters have an option to purchase an additional 1,350,000 shares.

S-1 filing: This is an S-1 filing for an initial public offering of common stock. The filing includes information on the company's executive compensation, risk factors, and summary financial data.

S-1/A filing: This S-1/A filing relates to the offering and resale by selling stockholders of up to 52,127,041 shares of common stock of Compass Therapeutics, Inc.

10-Q filing | 52.2M shares outstanding

S-1 filing: This prospectus relates to the offering and resale by the selling stockholders of up to 52,151,798 shares of common stock of Compass Therapeutics, Inc.

10-K filing | 5.0M shares outstanding

10-Q filing | 5.0M shares outstanding